Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.60 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.57 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3995960 | 0.86 | CYP4F2 (0.56) | SLC7A5CYP4F2CYP4A11ALDH1A1MAPT | |
| SCHEMBL2851334 | 0.84 | FOLH1 (0.54) | FOLH1MRGPRX4 | |
| SCHEMBL1790854 | 0.83 | SLC7A5 (0.68) | SLC7A5LOXL2CYP4F2CYP4A11FOLH1 | |
| SCHEMBL15609287 | 0.82 | SLC7A5 (0.76) | SLC7A5LOXL2CYP4F2CYP4A11FOLH1 | |
| SCHEMBL28281252 | 0.82 | SLC7A5 (0.76) | SLC7A5LOXL2CYP4F2CYP4A11FOLH1 | |
| SCHEMBL13589439 | 0.82 | SLC7A5 (0.76) | SLC7A5LOXL2CYP4F2CYP4A11FOLH1 | |
| Hydrochloric Acid SCHEMBL7735284 | 0.81 | SLC7A5 (0.74) | SLC7A5LOXL2CYP4F2CYP4A11FOLH1 | |
| SCHEMBL5505769 | 0.80 | CA1 (0.53) | SLC7A5LOXL2CYP4F2CYP4A11MRGPRX4 | |
| SCHEMBL5507004 | 0.80 | LMNA (0.53) | SLC7A5MRGPRX4SMN1; SMN2HPGDMEN1 | |
| SCHEMBL20257158 | 0.79 | SLC7A5 (0.63) | SLC7A5LOXL2CYP4F2CYP4A11FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2184285-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2184285-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-2049541-A2 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-04-22 | — | — | EP | disclosed |
| EP-2007737-A2 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| EP-2007736-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | AstraZeneca AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| EP-1966159-A2 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| EP-1966174-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| EP-1924573-A1 | B-RAF INHIBITORS | AstraZeneca AB (SE) | 2008-05-28 | — | — | EP | disclosed |
| EP-1765790-A1 | AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| EP-1761506-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006079791-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006067446-A1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067445-A2 | CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006040568-A1 | QUINOXALINES AS B RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006024834-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006024836-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006003378-A1 | AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005123696-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | SLC7A5 2834/4885LOXL2 2727/4885CYP4F2 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.